unpopular opinion: most of what gets said here about pharmacology is guesswork
Posting this as a discussion rather than a claim: unpopular opinion: most of what gets said here about pharmacology is guesswork.
Why mechanism talk keeps misleading people, including me.
A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.
The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
read the discussion section, that is where the honesty lives
read the discussion section, that is where the honesty lives
Agreed — and it is why the central and peripheral stories are complementary rather than rival.
the central appetite effect is doing more work than the gut effect
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Yes.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
The GIP question, which is the most interesting unsettled thing in this field.
Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.
It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.
Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.
preclinical is not clinical and rodents are not small people
This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.
tolerance to the gastric effect develops, appetite effect largely persists
glucagon agonism sounds paradoxical until you read the energy expenditure work
This.
This is the concept everything else on this board is downstream of.
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
a mechanism you can state is not a mechanism you have demonstrated
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
albumin binding is most of the half-life story
receptor agonism is not the same as receptor activation in every tissue
incretin effect first, then everything else in this board makes sense
dose response is not linear and nobody should assume it is
- 1The GIP question, which is the most interesting unsettled thing in this…10 comments in this branch · started by u/slow_logbook